Home » Topics » BioWorld Science, Cardiovascular

BioWorld Science, Cardiovascular
RSS

Venthera begins first-in-human trial of VT-30

Oct. 13, 2020

Topline data presented from phase III GALACTIC-HF study of omecamtiv mecarbil

Oct. 9, 2020

FDA grants IND approval for phase II/III study of CardiolRx in patients with COVID-19

Sep. 29, 2020

Quantum Genomics and collaborators present glutamyl aminopeptidase inhibitors

Sep. 29, 2020

Cytokinetics initiates phase I study of CK-3772271

Sep. 25, 2020

Circulating DPP3 inhibition restores cardiac function during sepsis in CLP rat models

Sep. 25, 2020

Genhouse Medicine identifies PTPN11 inhibitors

Sep. 25, 2020

Stem cell-derived CC exosomes improve MI recovery in pigs

Sep. 18, 2020

Regeneron initiates phase I study of NPR1 agonist REGN-5381

Sep. 16, 2020

L-606, inhaled liposomal treprostinil-extended release in healthy volunteers

Sep. 10, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Boehringer Ingelheim identifies new mGlu3 receptor agonists
BioWorld Science
Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...